Given the newly discovered roles CCL5 and its receptor CCR3 in bridging T/NK cells and the altered functions of smooth muscle, endothelial, and fibroblast cells, this ligand-receptor pair may be considered as potential drug targets in IPAH. The gene discussed is CCL5; the disease is idiopathic pulmonary arterial hypertension.